


Lifetime management aortální chlopně z pohledu kardiochirurga

P. Branny

Kardiocentrum Nemocnice Agel Třinec – Podlesí, a.s.

stárnutí populace

velmi široké použití
bioprotéz




bioprotéza

degenerace

stenóza/insuff


reoperace/ViV

life expectancy a aortální biochlopeč



Bagur et al. Heart 2017

EU vs US guidelines



TAVI vs SAVR (USA)

Figure 3 Rates of TAVR and SAVR From 2012 to 2019





Figure 2 Possible Clinical Decision Making in Aortic Stenosis



COMMENCE trial –

- 689 pacientů
- multicentrická studie (27 center)
- Ø věk pacienta 65,1 roku
- 7leté sledování

Hemodynamics @ 7 years

Clinically stable
hemodynamics




1.82 ± 0.57 cm²

Effective orifice area

9.4 ± 4.5 mmHg


Mean gradient

Outcomes @ 7 years (Kaplan-Meier analyses)



85.4%

Freedom from
all-cause mortality




97.2%

Freedom from
reoperation



99.3%

Freedom from SVD



99.4%

Freedom from valve
thrombosis



ESC

European Society
of Cardiology






European Heart Journal (2022) **43**, 2729–2750

<https://doi.org/10.1093/eurheartj/ehac105>

STATE OF THE ART REVIEW


Valvular heart disease

Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?

Stephan Windecker ^{1*}, **Taishi Okuno** ¹, **Axel Unbehaun** ^{2,3}, **Michael Mack**⁴,
Samir Kapadia ⁵, and **Volkmar Falk** ^{2,3,6,7}


¹Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland; ²Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, Berlin, Germany; ³DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; ⁴Baylor Scott & White Health, Baylor Scott & White Research Institute, Dallas, TX, USA; ⁵Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, OH, USA; ⁶Department of Cardiovascular Surgery, Charité University Hospital Berlin, Berlin, Germany; and ⁷ETH Zürich, Department of Health Sciences and Technology, Translational Cardiovascular Technology, Zurich, Switzerland

Received 13 October 2021; revised 22 February 2022; accepted 1 February 2022; online publish-ahead-of-print 23 April 2022



PARTNER 3 trial - 5leté výsledky

- Nízké chirurgické riziko
- Exkluze BAO
- Exkluze špatných femorálních přístupů





Five-year outcomes in trials comparing transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of reconstructed time-to-event data


Eur J Cardiothorac Surg 2022;61:977–87.

Fabio Barili ^{a,b,*}, Nicholas Freemantle^c, Francesco Musumeci^d, Barbara Martin^e, Amedeo Anselmi ^f, Mauro Rinaldi^g, Sanjay Kaul^h, Jorge Rodriguez-Roda ⁱ, Michele Di Mauro ^j, Thierry Folliguet^k, Jean-Philippe Verhoye^{f,t}, Miguel Sousa-Uva^{l,t} and Alessandro Parolari ^{m,n,t}; on behalf of the Latin European Alliance of CardioVascular Surgical Societies (LEACSS) and with the endorsement of the Latin American Association of Cardiac and Endovascular Surgery (LACES), LEACSS members are the Italian Society of Cardiac Surgery (FB FM MR Mdm AP), the Portuguese Society of Cardiac Surgery (MSU), the French Society of Cardiac Surgery (JFV, AA) and the Spanish Society of Cardiac Surgery (IRR) Institutions

- meta-analyza
- téměř 8 000 pac.



Srovnání: reoperace po TAVR a SAVR



TAVI in TAVI

- výška ACS, ACD


- výška neoskirt

- šířka bulbu



- VTA valve to Ao

- VTC coronariae


- VTSTJ STJ



valve in valve




lifetime management aortální náhrady



závěr

- Střednědobé výsledky TAVI jsou stejné nebo lepší jako SAVR
- Chybí informace o dlouhodobých výsledcích TAVI protéz
- Chirurgické bioprotézy mají prověřené dlouhodobé výsledky (Inspiris)
- Reoperace po TAVI mají výrazně vyšší mortalitu než po SAVR
- Při opakovaném použití bioprotézy se jeví jako vhodnější varianta jako první bio - SAVR



Děkuji za pozornost

(Tak si AI představuje spolupráci mezi TAVI a SAVR bioprotézami)